These results strongly suggest that we should detect ADAM12 in postoperative specimens from patients with CRC to better predict the survival time of patients or even to evaluate the status of the immune microenvironment to guide the use of immunotherapy drugs. This evidence concerns the gene ADAM12 and colorectal carcinoma.